Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Terbogrel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R known ✓ | P21731 | 20/20 | 0.75 |
| ▸ | TBXAS1 known ✓ | P24557 | 20/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terbogrel SCHEMBL13030802 | 1.00 | TBXA2R (0.75) | TBXA2RTBXAS1 | |
| Terbogrel SCHEMBL29383187 | 1.00 | TBXA2R (0.75) | TBXA2RTBXAS1 | |
| Terbogrel SCHEMBL7537032 | 1.00 | TBXA2R (0.75) | TBXA2RTBXAS1 | |
| Terbogrel SCHEMBL7537043 | 1.00 | TBXA2R (0.75) | TBXA2RTBXAS1 | |
| SCHEMBL9002323 | 0.97 | TBXA2R (0.74) | TBXA2RTBXAS1 | |
| SCHEMBL9002730 | 0.97 | TBXA2R (0.75) | TBXA2RTBXAS1 | |
| SCHEMBL9002333 | 0.94 | TBXA2R (0.73) | TBXA2RTBXAS1 | |
| SCHEMBL9002313 | 0.94 | TBXA2R (0.73) | TBXA2RTBXAS1 | |
| SCHEMBL9002321 | 0.94 | TBXA2R (0.73) | TBXA2RTBXAS1 | |
| SCHEMBL9002464 | 0.94 | TBXA2R (0.72) | TBXA2RTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1190714-A2 | Method for the treatment of thromboembolic disorders in patients with aspirin resistance | Schrör, Karsten, Prof. Dr. (DE) | 2002-03-27 | — | — | EP | claimed |
| EP-0547517-B1 | Pyridyl derivatives, medicines containing these compounds and processes for their preparation | THOMAE GMBH DR K (DE) | 1995-05-17 | — | — | EP | claimed |
| EP-0547517-A1 | Pyridyl derivatives, medicines containing these compounds and processes for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-06-23 | — | — | EP | claimed |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE LTD (SG) | 2025-09-04 | — | — | US | disclosed |
| EP-4291239-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE. LTD. (SG) | 2023-12-20 | — | — | EP | disclosed |
| WO-2022173333-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE. LTD. (SG) | 2022-08-18 | — | — | WO | disclosed |
| EP-1190714-A3 | Method for the treatment of thromboembolic disorders in patients with aspirin resistance | Schrör, Karsten, Prof. Dr. (DE) | 2002-04-03 | — | — | EP | disclosed |
| EP-1190714-A2 | Method for the treatment of thromboembolic disorders in patients with aspirin resistance | Schrör, Karsten, Prof. Dr. (DE) | 2002-03-27 | — | — | EP | disclosed |
| EP-1190714-A2 | Method for the treatment of thromboembolic disorders in patients with aspirin resistance | Schrör, Karsten, Prof. Dr. (DE) | 2002-03-27 | — | — | EP | disclosed |
| US-5482948-A | Pyridyl derivatives and pharmaceutical compositions comprising these compounds | DR. KARL THOMAE GMBH (DE) | 1996-01-09 | — | — | US | disclosed |
| EP-0547517-B1 | Pyridyl derivatives, medicines containing these compounds and processes for their preparation | THOMAE GMBH DR K (DE) | 1995-05-17 | — | — | EP | disclosed |
| EP-0547517-A1 | Pyridyl derivatives, medicines containing these compounds and processes for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | UPF1, NLN, BRCA1 | TBXA2R 4450/4885TBXAS1 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.